GRI Bio receives UAE patent allowance for inflammatory disease treatments

GRI Bio (GRI) announced it has received a Notice of Allowance from the United Arab Emirates Patent Office for a patent application covering novel type 2 diverse NKT cell agonists and related methods and compositions for the prevention and treatment of inflammatory conditions. “This Notice of Allowance reflects the continued execution of our disciplined global IP strategy,” said Marc Hertz, CEO of GRI Bio. “Securing protection in key international markets strengthens our platform and supports the advancement of our pipeline while creating additional opportunities for long-term value for shareholders.”